




Searching News Database: protein homeostasis
HSMN NewsFeed - 24 Aug 2022
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
HSMN NewsFeed - 20 Jan 2022
BioTheryX Announces Appointment of Sahm Nasseri as Chief Business Officer
BioTheryX Announces Appointment of Sahm Nasseri as Chief Business Officer
HSMN NewsFeed - 28 Oct 2021
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
HSMN NewsFeed - 3 Jan 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
HSMN NewsFeed - 17 Dec 2018
Proteostasis Therapeutics Announces Global License Agreement with Genentech
Proteostasis Therapeutics Announces Global License Agreement with Genentech
HSMN NewsFeed - 20 Oct 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
HSMN NewsFeed - 30 Jun 2014
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer
HSMN NewsFeed - 11 Oct 2011
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
HSMN NewsFeed - 10 Apr 2008
Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date